COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • July 28th, 2011 • Viropharma Inc • Pharmaceutical preparations • Delaware
THIS COLLABORATION AND LICENSE AGREEMENT (this “Agreement”), effective as of May 10, 2011 (the “Effective Date”) is entered into between HALOZYME, INC., a California corporation (“Halozyme”) and VIROPHARMA SPRL, a Belgian limited liability company (“ViroPharma”).
SECOND AMENDMENT TO PROJECT AGREEMENT No. 2 BETWEEN VIROPHARMA INCORPORATED AND NORWICH PHARMACEUTICALS, INC. (Formerly OSG Norwich Pharmaceuticals, Inc.)Project Agreement • July 28th, 2011 • Viropharma Inc • Pharmaceutical preparations • Pennsylvania
This Second Amendment amends that certain Project Agreement No. 2 between ViroPharma and NPI dated May 15, 2006, as amended (“Project Agreement No. 2”) entered into pursuant to the Master Agreement (the “Agreement”) and the Quality Agreement (the “Quality Agreement”) between ViroPharma and NPI dated as of December 1, 2005. The Second Amendment described herein relates to the extension of the term of Project Agreement No. 2 and changes to the fee structure if an abbreviated new drug application for a generic version of the Product is approved, and shall be governed by the terms, conditions and obligations set forth in the Agreement, the Quality Agreement, Project Agreement No. 2, as previously amended, and this Second Amendment. Terms not otherwise defined herein are set forth in the Project Agreement No. 2 and the Agreement. In consideration of the mutual covenants and agreements contained herein, ViroPharma and NPI, intending to be legally bound, do hereby agree as follows:
